DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Acecainide
Acecainide
Properties and Units in Clinical Pharmacology and Toxicology
Pharmaceutical Appendix to the Tariff Schedule 2
MICROMEDEX® Healthcare Series
Procainamide and Napa Immunogens, Antibodies Labeled Conjugates, and Related Derivatives
PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
Stembook 2018.Pdf
Antiarrhythmic Medications for Cardioversion and Maintenance Of
~~~~~~~~~Or Cardiacof Failure and Digoxin Toxicity May Producenas
Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
Physiological Scaling Factors and Mechanistic Models for Prediction of Renal Clearance from in Vitro Data
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
Package Insert
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Risk Markers for Cardiovascular Disease in Patients with Chronic Kidney Disease
Basics of EKG Interpretation
Ep 0158775 B1
Therapeutic and Toxic Blood Concentrations of More Than 1100 Drugs and Other Xenobiotics
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Top View
Package Insert
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances 2009
Pharmaceutical Appendix to the Tariff Schedule 2
Ligand P-Gp Inhibition
Pharmaceuticals Appendix
(12) United States Patent (10) Patent No.: US 7,026,360 B1 Fest0 (45) Date of Patent: Apr
(12) United States Patent (10) Patent No.: US 7,638,519 B2 Bush Et Al
(12) United States Patent (10) Patent No.: US 8,697,361 B2 Johnson (45) Date of Patent: Apr
Cyp3a Time Dependent Inhibition Risk Assessment
Therapeutic and Toxic Blood Concentrations of More Than 800 Drugs and Other Xenobiotics
Towards Predicting Drug-Induced Liver Injury (DILI): Parallel
Procainamide 3B40 34-3627/R5 Procainamide